Astellas Pharma Inc. (ALPMY)

Oncology Corporate Profile

Stock Performance

14.0500
-0.1400

HQ Location

Three Parkway North
Deerfield, IL 60015

Company Description

Astellas Pharma US, Inc., is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Located in Deerfield, Illinois, the company serves as the headquarters for the Americas and employs more than 2,300 people. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Website: http://www.astellas.us/

Brand Generic Indication
Tarceva«•erlotinibTARCEVA is a kinase inhibitor indicated for:



_Ê¢ Maintenance treatment of patients with locally advanced or metastatic non-small cell lung

cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based fi rst-line

chemotherapy.



_Ê¢ Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one

prior chemotherapy regimen.



_Ê¢ First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer,

in combination with gemcitabine.
Xtandi«• enzalutamideXTANDI is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
erlotinib tabletsHER1/EGFR tyrosine kinase inhibitor2nd line metastatic Non Small Cell Lung Cancer (NSCLC)IIIGenentech / Roche
gilteritinib / ASP2215tyrosine kinase inhibitorAcute Myelogenous Leukemia (AML)III
gilteritinib / ASP2215FLT3 tyrosine kinase inhibitorAcute Myelogenous Leukemia (AML)III
OSI-906dual IGF-1R and IR tyrosine kinase inhibitorAdrenocortical carcinoma (ACC)IIIOSI Pharmaceuticals
erlotinib tabletsHER1/EGFR tyrosine kinase inhibitorColorectal cancerIIIGenentech / Roche
enzalutamide / MDV3100androgen receptor inhibitorMetastatic hormone-sensitive Prostate cancerIII
ASP8273EGFR receptorNon Small Cell Lung Cancer (NSCLC)III
enzalutamide / MDV3100androgen receptor inhibitorNon-metastatic castration-resistant Prostate cancerIII
erlotinib tabletsHER1/EGFR tyrosine kinase inhibitorOvarian cancer IIIGenentech / Roche
ASP3550GnRH antagonistProstate cancerIII
enzalutamide / MDV3100androgen receptor inhibitorProstate cancer in patients with non-metastatic biochemical recurrence III
enzalutamide / MDV3100androgen receptor inhibitorTriple negative Breast cancer III
YM155survivin suppressant1st line metastatic Breast cancerII
OSI-906dual IGF-1R and IR tyrosine kinase inhibitor1st line metastatic Hepatocellular carcinoma (HCC)IIOSI Pharmaceuticals
AGS-1C4D4anti-PSCA monoclonal antibody (humanized)1st line metastatic Pancreatic cancerII
quizartinib / AC220FLT3 tyrosine kinase inhibitor2nd line metastatic Acute Myelogenous Leukemia (AML)IIAmbit Biosciences Inc.
blinatumomab / AMG 103anti-CD19 monoclonal antibodyAcute Lymphocytic Leukemia (ALL)II
YM155survivin suppressantB-cell Non-Hodgkin's Lymphoma (NHL)II
enzalutamide / MDV3100androgen receptor inhibitorBreast cancerII
enzalutamide / MDV3100androgen receptor inhibitorHepatocellular carcinoma (HCC)II
YM155survivin suppressantMelanomaII
OSI-906dual IGF-1R and IR tyrosine kinase inhibitorNon Small Cell Lung Cancer (NSCLC)IIOSI Pharmaceuticals
OSI-906dual IGF-1R and IR tyrosine kinase inhibitorOvarian cancerIIOSI Pharmaceuticals
AGS-16C3Fantibody drug conjugate (ADC)Renal cell carcinoma (RCC)II
enfortumab vedotin / ASG-22MEantibody drug conjugate (ADC)Urothelial cancerII
erlotinib tabletsHER1/EGFR tyrosine kinase inhibitorVarious cancer typesIIGenentech / Roche
Xtandi_ / enzalutamide (formerly MDV3100)oral androgen receptor antagonistBreast cancerIIMedivation
quizartinib (+ chemotherapy) / AC220FLT3 tyrosine kinase inhibitor1st line metastatic Acute Myelogenous Leukemia (AML)IAmbit Biosciences Inc.
AGS-16M8Fantibody drug conjugate (ADC)1st line metastatic Renal cell carcinoma (RCC)I
quizartinib / AC220FLT3 tyrosine kinase inhibitorAcute Myelogenous Leukemia (AML)IAmbit Biosciences Inc.
ASG-5MEantibody drug conjugate (ADC)Castrate-resistant Prostate cancer (CRPC)ISeattle Genetics
ASG-5MEantibody drug conjugate (ADC)Pancreatic cancerISeattle Genetics
ASP3026ALK inhibitorVarious cancer typesI
OSI-027mTOR inhibitorVarious cancer typesIOSI Pharmaceuticals
OSI-930VEGFR-2 inhibitorVarious cancer typesI
Xtandi_ / enzalutamideoral androgen receptor antagonistHepatocellular carcinoma (HCC)I
enzalutamide / MDV3100androgen receptor inhibitorMetastatic castration-resistant Prostate cancerApproved

View additional information on product candidates here »

Source


http://www.astellas.us/

Recent News Headlines

Astellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal Disease

2/28/2017 10:00 am

[Business Wire] - CAMBRIDGE, Mass. & TOKYO--(BUSINESSWIRE)-- Affinivax, Inc. ("Affinivax") and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae (pneumococcus). The partnership will utilize Affinivax’s proprietary vaccine technology platform – Multiple Antigen Presenting System (MAPS) – to advance a novel MAPS vaccine targeted to prevent and reduce the spread of pneumococcal disease. “I am pleased to enter into this agreement and partner with Affinivax to develop a pneumococcal vaccine using their novel MAPS technology.” said Kenji Yasukawa, Ph.D., Senior Vice President and Chief Strategy Officer of Astellas.

Astellas Reports the First Nine Months Financial Results of FY2016

1/31/2017 03:00 am

[Business Wire] - TOKYO--(BUSINESSWIRE)-- Astellas Pharma Inc. (TOKYO: 4503) (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced financial results for three quarters of fiscal year 2016 ending March 31, ...

Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan

1/30/2017 12:00 am

[Business Wire] - TOKYO & CAMBRIDGE, Mass.--(BUSINESSWIRE)-- Astellas Pharma Inc. (TSE:4503) and Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - News) announced today top-line results indicating that the Phase III clinical trial of linaclotide conducted in Japan in adults with chronic constipation (CC) met its primary endpoint. Linaclotide is approved in Japan as the first prescription treatment for adults with irritable bowel syndrome with constipation (IBS-C).

Astellas to Present at J.P. Morgan Healthcare Conference

12/21/2016 07:00 pm

[PR Newswire] - NORTHBROOK, Ill., Dec. 21, 2016 /PRNewswire/ -- Astellas US, LLC, a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced that the company's global President and CEO Yoshihiko Hatanaka will ...

Astellas Completes Acquisition of Ganymed Pharmaceuticals

12/21/2016 02:00 pm

[PR Newswire] - TOKYO, Dec. 21, 2016 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas" ) today announced that it has completed the acquisition of Ganymed Pharmaceuticals AG ("Ganymed"), a biopharmaceutical company located in Mainz, Germany, and Ganymed has become a wholly owned subsidiary of Astellas as of CET December 20, 2016. Under the agreement executed between Astellas and Ganymed's shareholders, Astellas paid EUR 422 million to acquire 100% of the equity in Ganymed.

Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in Japan for the Treatment of Adults with IBS-C

12/19/2016 11:00 am

[Business Wire] - CAMBRIDGE, Mass.--(BUSINESSWIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - News) today announced that its partner, Astellas Pharma Inc., secured marketing approval from the Japanese Ministry of Health, Labor and Welfare for LINZESS as the first prescription treatment for adults with irritable bowel syndrome with constipation (IBS-C) in Japan. Ironwood anticipates that Astellas will launch the drug in the first half of 2017. Linaclotide is a guanylate cyclase?C (GC?C) receptor agonist currently approved and available for the treatment of adults with IBS-C or chronic idiopathic constipation (CIC) in the United States and more than 30 other countries.

Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI® (enzalutamide) Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer

12/14/2016 09:01 pm

[Business Wire] - NEW YORK & TOKYO--(BUSINESSWIRE)-- Pfizer Inc. (NYSE:PFE - News) and Astellas Pharma Inc. (TSE:4503) today announced the Phase 4 PLATO study, evaluating the efficacy and safety of continued treatment with XTANDI® (enzalutamide), plus abiraterone acetate and prednisone as compared to treatment with abiraterone acetate and prednisone alone, did not meet its primary endpoint of improvement in progression-free survival (PFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (CRPC) whose prostate-specific antigen (PSA) has previously progressed on XTANDI. “While the PLATO trial did not meet its primary endpoint, it is critical that we continue to focus on addressing the unmet needs of men with metastatic CRPC, who have a poor prognosis despite treatment advances,” said Mohammad Hirmand, M.D., interim chief medical officer at Medivation, Inc., which is now part of Pfizer.

Astellas Research & Development Meeting Highlights

12/8/2016 03:03 am

[Business Wire] - TOKYO--(BUSINESSWIRE)-- Astellas Pharma Inc. (Tokyo: 4503, President and CEO: Yoshihiko Hatanaka, “the Company”) announced that it is holding a research and development (R&D) meeting for securities analysts, institutional investors and the press today on December 8, 2016. Also, the daily advances in scientific innovation represent new opportunities for Astellas. Against the social issue of expanding healthcare cost, Astellas conducts proactive efforts to achieve a balance between patients’ access to medicines and innovation as a pharmaceutical company.” said Yoshihiko Hatanaka, President and CEO of Astellas.

GUINNESS WORLD RECORDS™ Title Achieved for Organ Donor Registrations

11/8/2016 09:01 pm

[PR Newswire] - TOKYO and CHICAGO, Nov. 8, 2016 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, collectively with its subsidiaries "Astellas"), Donate Life America and the World Transplant Games Federation today announced that Astellas and Donate Life America registered thousands of new organ donors and tripled the previous GUINNESS WORLD RECORDS™ title for online organ donor registrations in an eight-hour period. During the same day, a record crowd for a rugby match held in America joined as Astellas provided a $175,000 USD contribution to the World Transplant Games Federation during a halftime celebration featuring transplant recipients from around the world.

Astellas to Acquire Ganymed Pharmaceuticals

10/28/2016 01:00 pm

[PR Newswire] - TOKYO and MAINZ, Germany, Oct. 28, 2016 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, ...

Astellas to Acquire Ganymed Pharmaceuticals

10/28/2016 12:15 pm

(Astellas) Oct 28, 2016 - Astellas Pharma Inc. and Ganymed Pharmaceuticals AG, a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed's shareholders have entered into an agreement for Astellas to acquire Ganymed. The transaction would enable Astellas to continue to build upon its leading oncology franchise as a platform for sustainable growth.

FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer

10/21/2016 03:05 pm

[PR Newswire] - TOKYO and NEW YORK, Oct. 21, 2016 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503) and Pfizer Inc. (PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for XTANDI® (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (CRPC) who were treated with enzalutamide compared to patients who were treated with bicalutamide.